Literature DB >> 26303809

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Paola Guglielmelli1, Giada Rotunno2, Costanza Bogani2, Carmela Mannarelli2, Laura Giunti3, Aldesia Provenzano3, Sabrina Giglio3, Matthew Squires4, Viktoriya Stalbovskaya4, Prashanth Gopalakrishna4, Alessandro M Vannucchi2.   

Abstract

Entities:  

Keywords:  CALR; JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; ruxolitinib

Mesh：

Substances：

Year:  2015        PMID： 26303809     DOI： 10.1111/bjh.13644

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  21 in total

Review 1.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 2.  JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.

Authors:  Michele Ciboddo; Ann Mullally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Mutant calreticulin in myeloproliferative neoplasms.

Authors:  Joan How; Gabriela S Hobbs; Ann Mullally
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

4.  JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

Authors:  G Barosi; C Klersy; L Villani; E Bonetti; P Catarsi; V Poletto; R Campanelli; S Impera; R Latagliata; G Viarengo; A Carolei; M Massa; M Musso; A Crescimanno; R P Gale; V Rosti
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

Review 5.  Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.

Authors:  Ross L Levine; Elodie Pronier; Tiffany R Merlinsky
Journal:  Clin Cancer Res       Date:  2019-01-17       Impact factor: 12.531

6.  Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Authors:  Manjola Balliu; Laura Calabresi; Niccolò Bartalucci; Simone Romagnoli; Laura Maggi; Rossella Manfredini; Matteo Lulli; Paola Guglielmelli; Alessandro Maria Vannucchi
Journal:  Blood Adv       Date:  2021-04-27

Review 7.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

Review 8.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

9.  MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.

Authors:  Shunichiro Yasuda; Satoru Aoyama; Ryoto Yoshimoto; Huixin Li; Daisuke Watanabe; Hiroki Akiyama; Kouhei Yamamoto; Takeo Fujiwara; Yuho Najima; Noriko Doki; Emiko Sakaida; Yoko Edahiro; Misa Imai; Marito Araki; Norio Komatsu; Osamu Miura; Norihiko Kawamata
Journal:  Int J Hematol       Date:  2021-06-24       Impact factor: 2.490

Review 10.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.